Drug · DIN 02525267
BIMZELX
PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 30, 2022; first marketed March 30, 2022.
- Drug Identification Number (DIN)
- 02525267
- Company (DIN owner)
- Ucb Canada IncOakville, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Bimekizumab L04AC21
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BIMEKIZUMAB | 160 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 14, 2022: NOC 27593New Drug Submission (NDS)
Other DINs named BIMZELX
- DIN 02525275 · Marketed
- DIN 02553619 · Marketed
- DIN 02553627 · Marketed